New pill may keep rare lymphoma in check after chemo
NCT ID NCT07300514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma (a rare blood cancer) from coming back after initial chemotherapy. About 136 adults who had a good response to first treatment but cannot or choose not to have a stem cell transplant will take either the drug or a placebo daily for up to 2 years. The goal is to see if the drug extends the time without cancer progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Engineered donor cells take on lymphoma in early trial
- Promising combo tackles rare blood cancer in chinese patients
- New drug cocktail aims to tackle rare blood cancer
- New drug combo shows promise for rare lymphoma in Real-World study
- Massive T-Cell lymphoma database aims to unlock new insights